Pro-senescence Therapy for Cancer: Time for the Clinic

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-94-017-9421-3_8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhanced killing of therapy‐induced senescent tumor cells by oncolytic measles vaccine viruses

  2014cited by this paper
• T-helper-1-cell cytokines drive cancer into senescence

  2013cited by this paper
• Proteome Of Amyloidosis: Mayo Clinic Experience In 4139 Cases

  2013cited by this paper
• ZNF313 is a novel cell cycle activator with an E3 ligase activity inhibiting cellular senescence by destabilizing p21WAF1

  2013cited by this paper
• MDM2, MDMX and p53 in oncogenesis and cancer therapy

  2013cited by this paper
• A complex secretory program orchestrated by the inflammasome controls paracrine senescence

  2013cited by this paper
• The Length of the Shortest Telomere as the Major Determinant of the Onset of Replicative Senescence

  2013cited by this paper
• The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.

  2013cited by this paper
• CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence

  2013cited by this paper
• Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

  2013cited by this paper
• Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study.

  2013cited by this paper
• APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

  2013cited by this paper
• Regulation of telomerase alternative splicing: a target for chemotherapy.

  2013cited by this paper
• RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer.

  2013cited by this paper
• p53 and regulation of tumor metabolism

  2013cited by this paper
• p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells

  2013cited by this paper
• Endoplasmic reticulum stress activates telomerase

  2013cited by this paper
• Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.

  2013cited by this paper
• Are Short Telomeres Hallmarks of Cancer Recurrence?

  2013cited by this paper
• Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production

  2012cited by this paper
• Glucocorticoids suppress selected components of the senescence‐associated secretory phenotype

  2012cited by this paper
• Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells.

  2012cited by this paper
• p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

  2012cited by this paper
• Epithelial-Mesenchymal Transition Induced by Senescent Fibroblasts

  2012cited by this paper
• Growth Inhibition by miR-519 via Multiple p21-Inducing Pathways

  2012cited by this paper
• Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

  2011cited by this paper
• Pro-senescence therapy for cancer treatment

  2011cited by this paper
• Senescence surveillance of pre-malignant hepatocytes limits liver cancer development

  2011cited by this paper
• A continuum model for tumour suppression

  2011cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.

  2011cited by this paper
• The essence of senescence.

  2010cited by this paper
• p53-based cancer therapy.

  2010cited by this paper
• Ras-induced senescence and its physiological relevance in cancer.

  2010cited by this paper
• A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.

  2010cited by this paper
• Senescent cells as a source of inflammatory factors for tumor progression

  2010cited by this paper
• Therapy-induced senescence in cancer.

  2010cited by this paper
• Subtle variations in Pten dose determine cancer susceptibility

  2010cited by this paper
• Myc, Cdk2 and cellular senescence: Old players, new game

  2010cited by this paper
• Identification of the miR-106b~25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation

  2010cited by this paper
• The p53 inducing drug dosage may determine quiescence or senescence

  2010cited by this paper
• The senescence-associated secretory phenotype: the dark side of tumor suppression.

  2010cited by this paper
• Targeting the PI3K signaling pathway in cancer.

  2010cited by this paper
• BRafV600E cooperates with Pten silencing to elicit metastatic melanoma

  2009cited by this paper
• p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence

  2009cited by this paper
• Activation of the PI3K Pathway in Cancer Through Inhibition of PTEN by Exchange Factor P-REX2a

  2009cited by this paper
• Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation.

  2009cited by this paper
• Autophagy mediates the mitotic senescence transition.

  2009cited by this paper
• An update on gene therapy in China.

  2009cited by this paper
• Sirtuins and p53.

  2009cited by this paper
• PTEN hamartoma tumor syndrome: An overview

  2009cited by this paper
• VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400

  2008cited by this paper
• Control of senescence by CXCR2 and its ligands

  2008cited by this paper
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  2008cited by this paper
• The role of senescence in the action of antitumor drugs.

  2008cited by this paper
• Many roads lead to oncogene-induced senescence

  2008cited by this paper
• Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

  2008cited by this paper
• Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network.

  2008cited by this paper
• Living on a break: cellular senescence as a DNA-damage response

  2008cited by this paper
• Tenets of PTEN tumor suppression.

  2008cited by this paper
• Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.

  2008cited by this paper
• Cellular senescence in cancer and aging.

  2007cited by this paper
• Cellular senescence: when bad things happen to good cells

  2007cited by this paper
• Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation

  2007cited by this paper
• Oncogene addiction: setting the stage for molecularly targeted cancer therapy.

  2007cited by this paper
• Essential role for nuclear PTEN in maintaining chromosomal integrity.

  2007cited by this paper
• New insight into BRAF mutations in cancer.

  2007cited by this paper
• Two faces of p53: aging and tumor suppression

  2007cited by this paper
• Restoration of p53 function leads to tumour regression in vivo

  2007cited by this paper
• A continuous correlation between oxidative stress and telomere shortening in fibroblasts.

  2007cited by this paper
• Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis

  2007cited by this paper
• Ubiquitination regulates PTEN nuclear import and tumor suppression.

  2007cited by this paper
• The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells.

  2007cited by this paper
• A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.

  2007cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.

  2006cited by this paper
• Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA

  2006cited by this paper
• Downregulation of MDM2 expression by RNAi inhibits LoVo human colorectal adenocarcinoma cells growth and the treatment of LoVo cells with mdm2siRNA3 enhances the sensitivity to cisplatin.

  2006cited by this paper
• Connective tissue diseases and cardiac rhythm disorders: an overview.

  2006cited by this paper
• A negative feedback signaling network underlies oncogene-induced senescence.

  2006cited by this paper
• Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication

  2006cited by this paper
• RAS unplugged: negative feedback and oncogene-induced senescence.

  2006cited by this paper
• The Myc oncoprotein as a therapeutic target for human cancer.

  2006cited by this paper
• Oncogene-induced senescence as an initial barrier in lymphoma development

  2005cited by this paper
• Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers.

  2005cited by this paper
• Novel MDM2 p53‐Independent Functions Identified through RNA Silencing Technologies

  2005cited by this paper
• Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

  2005cited by this paper
• BRAFE600-associated senescence-like cell cycle arrest of human naevi

  2005cited by this paper
• Tumour biology: Senescence in premalignant tumours

  2005cited by this paper
• Hallmarks of senescence in carcinogenesis and cancer therapy

  2004cited by this paper
• Targeted Delivery of Oncogene‐Selective Antisense Oligonucleotides in Neuroectodermal Tumors: Therapeutic Implications

  2004cited by this paper
• Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma.

  2004cited by this paper
• When cells get stressed: an integrative view of cellular senescence.

  2004cited by this paper
• Novel Small Molecule Cyclin-Dependent Kinases Modulators in Human Clinical Trials

  2003cited by this paper
• Tumor cell senescence in cancer treatment.

  2003cited by this paper
• A DNA damage checkpoint response in telomere-initiated senescence

  2003cited by this paper
• Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts

  2003cited by this paper
• ROS, stress‐activated kinases and stress signaling in cancer

  2002cited by this paper
• DNA damage is able to induce senescence in tumor cells in vitro and in vivo.

  2002cited by this paper
• A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.

  2002cited by this paper

• Cellular Senescence: Aging, Cancer, and Injury.

  2019cites this paper
• Modulation of therapy-induced senescence by reactive lipid aldehydes

  2016cites this paper